BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Patrys Limited to Acquire Assets of Acceptys, Inc.


10/29/2008 11:41:17 AM

Melbourne, Australia: 29 October, 2008: Australia’s human antibody therapy company, Patrys Limited (ASX:PAB), today announced its intention to acquire all of the technology assets of US-based company, Acceptys, Inc., including a pipeline of natural antibodies for infectious disease indications.

The assets acquired by Patrys include natural human antibodies directed at Hepatitis C, Staphylococcus A and Malaria, all significant unmet medical needs with commercial potential.

Under the agreement, Acceptys has agreed to cease all research activities in the antibody field, meaning that Acceptys’ exclusive rights to the Patrys natural human antibody platform for infectious disease applications, licensed to Acceptys in 2007, will terminate.

As it will no longer conduct research operations, Acceptys has agreed to transfer US$2 million to Patrys, representing nearly all of Acceptys’ cash reserves. Importantly, the infectious disease programs acquired by Patrys are currently being funded by collaborations of Acceptys, so Patrys has the complete discretion as to how and when to deploy these funds, including the option to dedicate them to existing Patrys oncology programs.

In return for gaining ownership of Acceptys’ technology and monetary assets, Patrys has agreed to issue Acceptys 11,300,000 ordinary shares (approximately 6.9% of the outstanding shares of the Company). Acceptys has indicated its intent to be a long-term shareholder of Patrys by agreeing to hold those shares under a twelve month escrow agreement.

The agreement between the parties also provides that Acceptys will release Patrys from ongoing milestone and royalty payments otherwise due on Patrys’ oncology assets (that were transferred by Acceptys to Patrys in January of 2007), and Patrys will forgo its 30% equity interest in Acceptys.

“Patrys has been able to expand our asset base through the addition of antibody programs aimed at infectious disease indications, and gain complete control over our natural antibody platform. At the same time, the Company has strengthened our financial position through the addition of cash and the elimination of royalty and milestone obligations on our oncology pipeline,” commented Dan Devine, Chief Executive Officer of Patrys. “This transaction immediately enhances the value of both internal development and partnering opportunities.”

The agreement is subject to shareholder approval at the 28 November, 2008 Patrys Annual General Meeting.

About Patrys Limited

Based in Melbourne, Australia, Patrys (ASX:PAB) is focused on the commercialization of its proprietary platform technologies for the capture, production and development of natural human antibodies as therapies for cancer and other major diseases. Patrys has a deep pipeline of anti-cancer natural human antibodies, two of which are schedules to enter human clinical trials starting in early 2009. In addition to its internal programs, Patrys has collaborations with several larger pharmaceutical companies to advance additional anti-cancer products from its pipeline. The Company has operations in Australia, Germany and the USA. For further information about Patrys, please refer to www.patrys.com

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES